Clinical and pharmacologic perspectives on the treatment of major depressive disorder

CNS Spectrums

Volumn 16, Issue 9, 2011, Pages 191-203

  Jefferson, James W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADD ON THERAPY; ALTERNATIVE MEDICINE; ARTICLE; AUTONOMIC NEUROPATHY; BECK DEPRESSION INVENTORY; CHEESE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FOOD DRUG INTERACTION; HAMILTON SCALE; HEART ARRHYTHMIA; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPERTHERMIA; HYPOMANIA; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER QUESTIONNAIRE; NEUROMUSCULAR DISEASE; PATIENT COMPLIANCE; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUICK INVENTORY OF DEPRESSION SELF REPORT; RELAPSE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; WINE; ZUNG SELF RATING DEPRESSION SCALE;

EID: 80053320747     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852912000375     Document Type: Article

References (98)

1. Goodwin GM. Major depression is sometimes described as the common cold of psychiatry. J Psychopharmacol. 2008;22(7 suppl):3.
2. Silverman C. The Epidemiology of Depression. Baltimore, MD: Johns Hopkins University Press; 1969.
3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-627.
4. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
5. Kessler RC, Berglund P, Demler OZ, et al, for the National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
6. The Management of MDD Working Group. Management of major depressive disorder (MDD). Available at www.healthquality.va.gov/mdd/mdd_full09_c.pdf. Accessed March 15, 2010.
7. González HM, Vega WA, Williams DR, Tarraf W, West BT, Neighbors HW. Depression care in the United States: too little for too few. Arch Gen Psychiatry. 2010;67(1):37-46.
8. American Foundation for Suicide Prevention. Fact and figures: national statistics. Available at www.afsp.org/index.cfm?fuseaction=home.viewpage&page_id=050fea9f-b064-4092-b1135c3a70de1fda. Accessed March 15, 2010.
9. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327-337.
10. Kusmider M, Faron-Górecka A, Dziedzicka-Wasylewska M. Delayed effects of antidepressant drugs in rats. Behav Pharmacol. 2006;17(8):641-649.
11. Kornum BR, Weikop P, Moller A, Ronn LC, Knudsen GM, Aznar S. Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Res. 2006;1073-1074:262-268.
12. Moreno FA, Heninger GR, McGahuey CA, Delgado PL. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry. 2000;48(4):327-329.
13. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12(4):331-359.
14. Stahl S. Stahl's Essential Psychopharmacology Online. 3rd edition. Available at http://stahlonline.cambridge.org/essential_chapter.jsf?page=chapter6_7.htm&name=Chapter%206&title=De. Accessed March 15, 2010.
15. Husain MM, Rush AJ, Wisniewski SR, et al. Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry. 2009;70(2):185-195.
16. Verhagen M, van der Meij A, Franke B, et al. Familiality of major depressive disorder and gender differences in comorbidity. Acta Psychiatr Scand. 2008;118(2):130-138.
17. Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21(1):14-18.
18. Nuyen J, Schellevis FG, Satariano WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol. 2006;59(12):1274-1284.
19. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54(3):227-240.
20. Agency for Healthcare Research and Quality. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. 2007. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=7%20&DocID=61. Accessed March 15, 2010.
21. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65(8):870-880.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. Washington, DC; American Psychiatric Association; 2000.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Available at www.dsm5.org. Accessed February 18, 2010.
24. Wakefield JC, Schmitz MF, Baer JC. Does the DSM-IV clinical significance criterion for major depression reduce false positives? Evidence from the National Comorbidity Survey Replication. Am J Psychiatry. 2010;167(3):298-304.
25. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(18):1329-1335.
26. Stromberg R, Wernering E, Aberg-Wistedt A, Furhoff AK, Johansson SE, Backlund LG. Screening and diagnosing depression in women visiting GPs' drop in clinic in primary Health Care. BMC Fam Pract. 2008;9:34.
27. Sheikh RM, Weller EB, Weller RA. Prepubertal depression: diagnostic and therapeutic dilemmas. Curr Psychiatry Rep. 2006;8(2):121-126.
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
29. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
30. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18(1):65-87.
31. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486.
32. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
33. Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer. 1991;64(2):353-356.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
35. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
36. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
37. Gelenberg A, Freeman MP, Markowitz JC, Rosenbaum JF, et al, for the American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, ed 3. Available at http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm. Accessed August 14, 2011.
38. Fochtmann LJ, Gelenberg AG. Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, ed 2. Available at www.psychiatryonline.com/content.aspx?aid=148217. Accessed March 16, 2010.
39. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. J Affect Disord. 2009;117(suppl 1):S1-S64.
40. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-1006.
41. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157(2):229-233.
42. Agency for Healthcare Research and Quality. Choosing antidepressants for adults: clinician's guide. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=sg&DocID=9&ProcessID=7. Accessed March 16, 2010.
43. Solomon DA, Leon AC, Maser JD, Truman CJ, Coryell W, Endicott J. Distinguishing bipolar major depression from unipolar major depression with the screening assessment of depression-polarity (SAD-P). J Clin Psychiatry. 2006;67(3):434-442.
44. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873-1875.
45. Gervasoni N, Weber Rouget B, Miguez M, et al. Performance of the Mood Disorder Questionnaire (MDQ) according to bipolar subtype and symptom severity. Eur Psychiatry. 2009;24(5):341-344.
46. Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry. 2004;65(4):485-491.
47. Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT. 2003;19(3):139-147.
48. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799-808.
49. Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry. 2000;57(6):581-590.
50. McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000;57(5):438-444.
51. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425-434.
52. Kennedy SH, Milev R, Giacobbe P, et al, for the Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: IV. Neurostimulation therapies. J Affect Disord. 2009;117(suppl 1):S44-S53.
53. Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med. 2009;71(2):235-242.
54. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009;42(2):5-38.
55. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. J Affect Disord. 2009;118(1-3):94-100.
56. Even C, Schröder CM, Friedman S, Rouillon F. Efficacy of light therapy in nonseasonal depression: a systematic review. Affect Disord. 2008;108(1-2):11-23.
57. Westrin A, Lam RW. Long-term and preventative treatment for seasonal affective disorder. CNS Drugs. 2007;21(11):901-909.
58. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162(4):656-662.
59. Parker G. What is the place of psychological treatments in mood disorders? Int J Neuropsychopharmacol. 2007;10(1):137-145.
60. Parikh SV, Segal ZV, Grigoriadis S, et al, for the Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117(suppl 1):S15-S25.
61. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry. 2008;69(11):1675-1685.
62. Zhang ZJ, Chen HY, Yip KC, Ng R, Wong VT. The effectiveness and safety of acupuncture therapy in depressive disorders: systematic review and meta-analysis. J Affect Disord. 2010;124(1-2):9-21.
63. Uebelacker LA, Epstein-Lubow G, Gaudiano BA, Tremont G, Battle CL, Miller IW. Hatha yoga for depression: critical review of the evidence for efficacy, plausible mechanisms of action, and directions for future research. J Psychiatr Pract. 2010;16(1):22-33.
64. Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry. 2003;5(4):153-157.
65. Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65(1):94-101.
66. Skaer TL, Sclar DA, Robison LM. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin Ther. 2009;31(pt 1):1478-1487.
67. Trivedi MH, Rush AJ, Wisniewski SR. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
68. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
69. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
70. Fountoulakis KN, Möller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol. 2010; August 27 [Epub ahead of print].
71. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-750.
72. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685-1695.
73. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
74. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract. 2003;9(5):376-384.
75. Preskorn SH. Outpatient management of depression. Available at www.preskorn.com/books/omd_s10.html. Accessed March 16, 2010.
76. US Food and Drug Administration. Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Available at www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm168828.htm. Accessed March 16, 2010.
77. UK Medicines and Healthcare Products Regulatory Agency. Selective serotonin re-uptake inhibitors (SSRIs). Available at www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Selectiveserotoninre-uptakeinhibitors/index.htm. Accessed March 16, 2010.
78. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-2107.
79. van Geffen EC, Kruijtbosch M, Egberts AC, Heerdink ER, van Hulten R. Patients' perceptions of information received at the start of selective serotonin-reuptake inhibitor treatment: implications for community pharmacy. Ann Pharmacother. 2009;43(4):642-649.
80. Shigemura J, Sato Y, Yoshino A, Nomura S. Patient satisfaction with antidepressants: an Internet-based study. J Affect Disord. 2008;107(1-3):155-160.
81. Jefferson JW. Bupropion extended-release for depressive disorders. Expert Rev Neurother. 2008;8(5):715-722.
82. McLaughlin T, Hogue SL, Stang PE. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am J Ther. 2007;14(2):221-225.
83. Stang P, Young S, Hogue S. Better patient persistence with once-daily bupropion compared with twice-daily bupropion. Am J Ther. 2007;14(1):20-24.
84. Henshall DC, Dürmüller N, White HS, et al. Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents. Neuropsychiatr Dis Treat. 2009;5:189-206.
85. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
86. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
87. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
88. Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57-90.
89. Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs. 2001;10(10):1789-1796.
90. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61(5):676-697.
91. Butterweck V. Mechanism of action of St John's wort in depression: what is known? CNS Drugs. 2003;17(8):539-562.
92. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database of Systematic Reviews. 2008;(4):CD000448.
93. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):118-127.
94. Freeman MP. Complementary and alternative medicine for perinatal depression. J Affect Disord. 2009;112(1-3):1-10.
95. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056-1061.
96. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167:942-948.555.
97. de Jonghe F, Kool S, van Aalst G, Dekker J. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord. 2001;64(2-3):217-229.
98. Pampallona S, Bollini P, Giuseppe T, Kupelnick B Munizz C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61(7):714-719.